Abbott Laboratories (ABT) EBIT Margin (2009 - 2026)

Abbott Laboratories has disclosed EBIT Margin across 18 years of filings, most recently posting 12.05% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 12.05%, down 430.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.07% (up 23.0% YoY), and the FY2025 annual result was 18.17%, up 190.0% from the prior year.
• EBIT Margin came in at 12.05% for Q1 2026 at Abbott Laboratories, down from 19.64% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 24.48% in Q1 2022 to a low of 12.05% in Q1 2026.
• The 5-year median for EBIT Margin is 17.0% (2022), against an average of 17.03%.
• Across the five-year window, EBIT Margin surged 749 bps in 2022 and slumped 900 bps in 2023, its largest moves.
• Abbott Laboratories' EBIT Margin stood at 12.92% in 2022, then jumped by 35 bps to 17.38% in 2023, then climbed by 0 bps to 17.41% in 2024, then gained by 13 bps to 19.64% in 2025, then slumped by 39 bps to 12.05% in 2026.
• The last three EBIT Margin figures came in at 12.05% (Q1 2026), 19.64% (Q4 2025), and 18.09% (Q3 2025), per Business Quant data.